Product News

Hand-coded TLFs stall NDA filings: this CRO cut them to a week

Clene reached its 2026 ALS filing after automated statistical engines turned locked trial data into submission-ready outputs in days
Written bySharon Dong
Brought to you byVeristat
| 4 min read
Illustration of biostatistical TLF automation showing clinical trial data flowing from database lock through validated statistical engines to submission-ready tables, listings, and figures for an NDA.

Biostatistical TLF automation compresses the path from database lock to NDA submission, the costliest stretch of late-stage clinical trials.

Google Flow

After the last patient visit and the final data query, a clinical trial enters one of its least visible but most consequential stretches: the gap between database lock and regulatory submission. Biostatisticians hand-program, validate, and double-program the tables, listings, and figures (TLFs) that regulators actually read, a process that routinely consumes weeks per cycle. Industry analyses place the cost of each lost day at roughly half a million dollars in unrealized sales.

The stakes climb higher in fatal, rapidly progressing diseases such as amyotrophic lateral sclerosis (ALS), where median survival after diagnosis runs two to five years. Sponsors typically respond by adding programmers, a remedy that scales poorly when the volume of required analyses expands late in a filing.

Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that its InStat biometrics platform cut the time to deliver validated biostatistical outputs for Clene Nanomedicine's pivotal ALS drug application by 80 percent. The interval from locked study data to submission-ready TLFs fell from up to six weeks to one week. Clene is a late-stage biotechnology company.

ALS accelerated approval: NfL analyses on the critical path

Clene's October 2026 accelerated approval NDA, a New Drug Application for CNM-Au8 in ALS filed under the US Food and Drug Administration's (FDA) Subpart H pathway, rests heavily on neurofilament light (NfL) biomarker analyses. NfL, a blood-based marker of neuronal injury, anchors the submission because the FDA indicated in a Type C meeting that the biomarker could potentially serve as a reasonably likely surrogate endpoint in ALS. The NfL analysis package, not a conventional clinical endpoint readout, therefore formed the statistical center of gravity of the application.

When the volume of required analyses expanded beyond the original plan, InStat allowed Clene to absorb the added work and still submit in 2026. The engagement spanned a dozen deliverables, each governed by its own statistical analysis plan; Veristat reported comparable results on two studies for a second sponsor.

"Veristat moved at unprecedented speed, eliminating weeks of hand-programming that is also the source of most errors," said Rob Etherington, CEO of Clene Nanomedicine. "Every minute from database lock to submission matters. InStat enabled us to move from locked data to reviewable NfL biomarker tables in days, allowing for concurrent review and verification of the outputs instead of waiting until the end of a long cycle. That kind of speed, with the rigor we require, is what lets us keep pace with the urgency of ALS."

How does InStat automate TLFs without LLM-generated code?

InStat does not ask a large language model (LLM) to write analysis programs. Artificial intelligence (AI) agents instead translate biostatisticians' descriptions into machine-readable specifications. The design aims to deliver automation speed without the regulatory exposure of LLM-generated analysis code:

  • Zero-code specification: AI agents convert biostatistician descriptions into formal analysis specifications
  • Validated engines: a pre-built library of statistical engines, not generated code, performs every computation
  • Traceability: each output links back to its specification for regulatory audit
  • Expert review: Veristat biostatisticians review every deliverable before release
  • System-agnostic design: sponsors keep their preferred electronic data capture system and formatting standards
  • One-week turnaround: reported delivery of submission-ready TLFs within days of database lock

"Everyone hoped AI would bring speed, but quality may be the bigger story," said Kyle McBride, Vice President of AI & Innovation at Veristat. "In every side-by-side comparison with traditional hand programming, any discrepancies traced back to the manual side, never to InStat. An error in an NDA puts an approval at risk. While much of the industry is still working on either speed, quality, or compliance, we've solved all three. Faster used to mean riskier. Not anymore, and that means new therapies can reach patients sooner."

A one-week TLF cycle changes submission economics

Compressing the TLF cycle from six weeks to one carries a quantifiable economic value, according to independent, peer-reviewed estimates rather than vendor claims. In a 2024 analysis in Therapeutic Innovation & Regulatory Science, lead author Zachary P. Smith, coauthor Joseph A. DiMasi, and senior author Kenneth A. Getz of the Tufts Center for the Study of Drug Development recalculated delay-day costs at approximately $500,000 per day in unrealized sales, replacing a decades-old $4 million estimate. The same analysis put direct trial conduct costs at $40,000 per day on average and above $55,000 per day for Phase 3 studies.

By those estimates, five weeks recovered on the critical path represents on the order of $17.5 million in earlier-realized sales value. The Tufts authors cautioned that the per-day figure declines by roughly $80,000 each year. The table below summarizes how the automated and manual workflows compare.

AttributeTraditional manual TLF programmingInStat automated workflow
Time from database lock to validated TLFsUp to six weeks per cycleApproximately one week
Code sourceHand-programmed and double-programmed by statisticiansPre-validated statistical engine library
Specification processManual statistical programming specificationsAI agents convert biostatistician descriptions into specifications
Review modelSequential review at end of programming cycleConcurrent review and verification of outputs
Reported error pattern in side-by-side comparisonsDiscrepancies traced to manual programmingNo discrepancies attributed to platform, per Veristat

Company performance claims, including the 80 percent reduction and the side-by-side error comparisons, reflect Veristat's reported results for this engagement and have not been independently published.

Automated TLFs kept Clene's ALS accelerated approval on schedule

Veristat's InStat platform cut validated TLF delivery for Clene's CNM-Au8 ALS submission from up to six weeks to one, an 80 percent reduction that let an expanded NfL analysis package reach the FDA in 2026. The approach pairs AI-written specifications with pre-validated statistical engines rather than LLM-generated code, keeping every output traceable and biostatistician-reviewed. With the FDA's review decision ahead, a Phase 3 confirmatory study planned for 2027, and InStat already deployed on a second sponsor's studies, the collaboration offers an early model for how automated biostatistics can shorten the path from database lock to regulatory submission.

This article is based on a press release issued by Veristat and was produced under Drug Discovery News' AI Editorial Guidelines.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • black and white picture of sharon dong in button up blouse
    Sharon Dong, BSc (Hons), MSc joined LabX Media Group (LMG) in 2026 as a Product News & Intelligence Editor. She has a strong background in cellular biology, microbiology, immunology, and molecular genetics. She is an experienced science education and outreach facilitator. Sharon is passionate about communicating science in ways that are clear, engaging, and accessible to a broad audience. In her free time, she enjoys solving jigsaw puzzles and cooking. Sharon can be reached at sdong@labx.com.
    View Full Profile

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.